Sarcolemmal ATP-sensitive potassium channel (sarcKATP)

The sarcolemmal ATP-sensitive potassium channel (sarcKATP) is a metabolic sensor located in the plasma membrane of muscle cells, primarily cardiomyocytes (PubMed: 12163444). It is a heterooctameric complex composed of four pore-forming Kir6.2 subunits (UniProt: P48048) and four regulatory sulfonylurea receptor 2A (SUR2A) subunits (UniProt: Q14654). The channel couples cellular metabolism to electrical activity by responding to the intracellular ATP/ADP ratio; it remains closed when ATP is high and opens when ATP levels drop during metabolic stress (PubMed: 16103305). Opening of the channel during ischemia leads to potassium efflux, which hyperpolarizes the cell and shortens the action potential duration, providing a critical cardioprotective effect by reducing calcium overload (PubMed: 11166215). Pharmacologically, sarcKATP is targeted by potassium channel openers like Nicorandil for the treatment of angina (StatPearls: Potassium Channel Openers). Conversely, mutations in its constituent subunits are associated with diseases such as Cantu syndrome and certain forms of cardiac arrhythmia (PubMed: 22941191). While beneficial in the heart, non-selective modulation can lead to safety concerns such as hypotension or hypoglycemia due to effects on vascular or pancreatic KATP isoforms (PubMed: 15151919).

Other names

Sarcolemmal KATP channelCardiac KATP channelKir6.2/SUR2A complexATP-sensitive inward rectifier potassium channelsarcKATP

The channel modulates potassium conductance across the sarcolemma in response to the intracellular ATP/ADP ratio. Agonists (openers) promote potassium efflux to hyperpolarize the cell and shorten action potential duration, while antagonists (blockers) inhibit this efflux to maintain depolarization.